Medical News |
- Rivaroxaban reduces risk for death from CV cause, MI, or stroke in ACS
- Increasing colonoscopy capacity improves FIT screening benefits
- Predictors for mood episode course and relapse in BD identified
- Cell cycle dynamics altered in schizophrenia patients
- Rivaroxaban reduces risk for death from CV cause, MI, or stroke in ACS
- Intracoronary abciximab no better than intravenous delivery for STEMI treatment
- Bivalirudin preferred for PCI in AMI with or without ST-elevation
- Warfarin use raises IVH risk, severity in event of ICH
- Warfarin use raises IVH risk, severity in event of ICH
- Intracoronary abciximab no better than intravenous delivery for STEMI treatment
- Bivalirudin preferred for PCI in AMI with or without ST-elevation
| Rivaroxaban reduces risk for death from CV cause, MI, or stroke in ACS Posted: 14 Nov 2011 04:00 PM PST The factor Xa inhibitor rivaroxaban significantly reduces the incidence of death from cardiovascular causes, myocardial infarction, or stroke in patients with a recent acute coronary syndrome, show results of the ATLAS ACS 2-TIMI 51 trial. |
| Increasing colonoscopy capacity improves FIT screening benefits Posted: 14 Nov 2011 04:00 PM PST The fecal immunochemical test has significant health and cost benefits over use of guaiac fecal occult blood testing for the detection of colorectal cancer, US researchers believe. |
| Predictors for mood episode course and relapse in BD identified Posted: 14 Nov 2011 04:00 PM PST Affective and cognitive measures, as well as personality factors, are important predictors for mood episode course and relapse in patients with bipolar disorder, research shows. |
| Cell cycle dynamics altered in schizophrenia patients Posted: 14 Nov 2011 04:00 PM PST Results from an Australian study suggest that cell cycle dynamics are altered in schizophrenia patients compared with mentally healthy individuals. |
| Rivaroxaban reduces risk for death from CV cause, MI, or stroke in ACS Posted: 14 Nov 2011 04:00 PM PST The factor Xa inhibitor rivaroxaban significantly reduces the incidence of death from cardiovascular causes, myocardial infarction, or stroke in patients with a recent acute coronary syndrome, show results of the ATLAS ACS 2-TIMI 51 trial. |
| Intracoronary abciximab no better than intravenous delivery for STEMI treatment Posted: 13 Nov 2011 04:00 PM PST Intracoronary administration of the glycoprotein IIb/IIIa inhibitor abciximab does not improve overall health outcomes over intravenous delivery in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention, show results from the AIDA STEMI trial. |
| Bivalirudin preferred for PCI in AMI with or without ST-elevation Posted: 13 Nov 2011 04:00 PM PST A head-to-head comparison of a combination of abciximab and unfractionated heparin versus bivalirudin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention shows that the efficacy of the two therapies are virtually identical. |
| Warfarin use raises IVH risk, severity in event of ICH Posted: 13 Nov 2011 04:00 PM PST Warfarin worsens intracerebral hemorrhage outcomes by affecting intraventricular hemorrhage risk and severity, research suggests. |
| Warfarin use raises IVH risk, severity in event of ICH Posted: 13 Nov 2011 04:00 PM PST Warfarin worsens intracerebral hemorrhage outcomes by affecting intraventricular hemorrhage risk and severity, research suggests. |
| Intracoronary abciximab no better than intravenous delivery for STEMI treatment Posted: 13 Nov 2011 04:00 PM PST Intracoronary administration of the glycoprotein IIb/IIIa inhibitor abciximab does not improve overall health outcomes over intravenous delivery in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention, show results from the AIDA STEMI trial. |
| Bivalirudin preferred for PCI in AMI with or without ST-elevation Posted: 13 Nov 2011 04:00 PM PST A head-to-head comparison of a combination of abciximab and unfractionated heparin versus bivalirudin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention shows that the efficacy of the two therapies are virtually identical. |
| You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment